Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Brain metastasis: opportunity for drug development?

Preusser M, Berghoff AS, Schadendorf D, Lin NU, Stupp R.

Curr Opin Neurol. 2012 Dec;25(6):786-94. doi: 10.1097/WCO.0b013e328359320d. Review.

PMID:
23108247
2.

Molecular subtyping of brain metastases and implications for therapy.

Renfrow JJ, Lesser GJ.

Curr Treat Options Oncol. 2013 Dec;14(4):514-27. doi: 10.1007/s11864-013-0248-2.

PMID:
23907440
3.

Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.

Lombardi G, Di Stefano AL, Farina P, Zagonel V, Tabouret E.

Cancer Treat Rev. 2014 Sep;40(8):951-9. doi: 10.1016/j.ctrv.2014.05.007. Epub 2014 May 27. Review.

PMID:
24909312
4.

The role of EGFR inhibitors in nonsmall cell lung cancer.

Ciardiello F, De Vita F, Orditura M, Tortora G.

Curr Opin Oncol. 2004 Mar;16(2):130-5. Review.

PMID:
15075904
5.

Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.

Schouten LJ, Rutten J, Huveneers HA, Twijnstra A.

Cancer. 2002 May 15;94(10):2698-705.

6.

Chemoprevention for brain metastases.

Trinh VA, Hwu WJ.

Curr Oncol Rep. 2012 Feb;14(1):63-9. doi: 10.1007/s11912-011-0200-1. Review.

PMID:
22006097
7.

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.

Sandler A, Hirsh V, Reck M, von Pawel J, Akerley W, Johnson DH.

Lung Cancer. 2012 Oct;78(1):1-7. doi: 10.1016/j.lungcan.2012.07.004. Epub 2012 Aug 9. Review.

PMID:
22877947
8.

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.

Jamal-Hanjani M, Spicer J.

Clin Cancer Res. 2012 Feb 15;18(4):938-44. doi: 10.1158/1078-0432.CCR-11-2529. Epub 2011 Dec 13. Review.

9.

Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.

Tomasello G, Bedard PL, de Azambuja E, Lossignol D, Devriendt D, Piccart-Gebhart MJ.

Crit Rev Oncol Hematol. 2010 Aug;75(2):110-21. doi: 10.1016/j.critrevonc.2009.11.003. Epub 2009 Dec 9. Review.

PMID:
20004109
10.

CNS complications of breast cancer: current and emerging treatment options.

Kaal EC, Vecht CJ.

CNS Drugs. 2007;21(7):559-79. Review.

PMID:
17579499
11.

Medical management of brain metastases from lung cancer (Review).

Yamanaka R.

Oncol Rep. 2009 Dec;22(6):1269-76. Review.

PMID:
19885576
12.

Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.

Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, Carlini P, Boni C, Di Sarra S.

Cancer. 1999 Apr 1;85(7):1599-605.

PMID:
10193952
13.

First International Symposium on Melanoma and Other Cutaneous Malignancies.

Tarhini AA, Agarwala SS.

Expert Opin Biol Ther. 2004 Sep;4(9):1541-6.

PMID:
15335320
14.

Targeted therapy for brain metastases.

Davies MA.

Adv Pharmacol. 2012;65:109-42. doi: 10.1016/B978-0-12-397927-8.00005-1. Review.

PMID:
22959025
15.

Targeted therapy in brain metastasis.

Soffietti R, Trevisan E, Rudà R.

Curr Opin Oncol. 2012 Nov;24(6):679-86. doi: 10.1097/CCO.0b013e3283571a1c. Review.

16.

Brain metastases: pathobiology and emerging targeted therapies.

Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A.

Acta Neuropathol. 2012 Feb;123(2):205-22. doi: 10.1007/s00401-011-0933-9. Epub 2012 Jan 3. Review.

PMID:
22212630
17.

Drug development for cancer chemoprevention: focus on molecular targets.

Johnson KA, Brown PH.

Semin Oncol. 2010 Aug;37(4):345-58. doi: 10.1053/j.seminoncol.2010.05.012. Review.

PMID:
20816505
18.

Long-term survival with metastatic cancer to the brain.

Hall WA, Djalilian HR, Nussbaum ES, Cho KH.

Med Oncol. 2000 Nov;17(4):279-86.

PMID:
11114706
19.

Systemic treatment in breast-cancer patients with brain metastasis.

Arslan C, Dizdar O, Altundag K.

Expert Opin Pharmacother. 2010 May;11(7):1089-100. doi: 10.1517/14656561003702412. Review.

PMID:
20345334
20.

Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.

Milas I, Komaki R, Hachiya T, Bubb RS, Ro JY, Langford L, Sawaya R, Putnam JB, Allen P, Cox JD, McDonnell TJ, Brock W, Hong WK, Roth JA, Milas L.

Clin Cancer Res. 2003 Mar;9(3):1070-6.

Supplemental Content

Support Center